DBV Technologies | DBVT - Operating Profit


DBV Technologies reported $-47.9M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amarin USD -2.26M 564K Dec/2025
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
DBV Technologies USD -47.9M 2.85M Mar/2026
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Incyte USD 700.4M 376.22M Jun/2026
Insmed USD -200.28M 49.43M Mar/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
United Therapeutics USD 330.8M 5M Jun/2026